Myung In Pharm Co

Myung In Pharm Co Net Margin

The Net Profit Margin of Myung In Pharm Co (317450.KS) as of Nov 18, 2026 is 28.35 %. In the previous year, Net Profit Margin was 25.49 % — a change of 11.23% (higher).

Net Margin

28.35 %

YoY

11.23%

Last updated:

Net Profit Margin of Myung In Pharm Co is 2025 28.35 % . Net Profit Margin of Myung In Pharm Co was 2024 25.49 % . It decreases by 11.23% higher compared to the previous year.

For Myung In Pharm Co, the net margin of 28.3% is down versus 30.7% a few years ago.

The Myung In Pharm Co Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2023
30.75 KRW
Jan 1, 2024
25.49 KRW
Jan 1, 2025
28.35 KRW
The Myung In Pharm Co Net Margin history
YEARNet MarginYoY
28.35 %+11.23%
25.49 %-17.11%
30.75 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Myung In Pharm Co Stock analysis

What does Myung In Pharm Co do? Myung In Pharm Co., Ltd. generates revenue through the manufacture and sale of prescription drugs for neurology and psychiatry, including stroke and Parkinson’s disease treatments, schizophrenia, and depression therapies. The company primarily targets domestic and overseas markets, distributing its products under its own brand for neurological and psychiatric conditions. General pharmaceuticals such as dental, oral, digestive system treatments, and other related products form additional revenue streams within its domestic and international sales channels. The firm focuses on prescription drug segments, with key products addressing stroke, Parkinson’s disease, schizophrenia, and depression. These treatments are sold directly to healthcare providers and pharmacies in both domestic and overseas markets. The company also offers general pharmaceuticals like dental and oral treatments, alongside digestive system therapies, contributing to its diversified product portfolio across multiple therapeutic areas. Myung In Pharm’s business model relies on selling branded prescription medications for specific neurological and psychiatric conditions, alongside general pharmaceuticals. Its domestic and overseas market presence ensures consistent revenue from both regional and global healthcare sectors, with no additional details on specific customer segments or pricing strategies disclosed in the provided description. Myung In Pharm Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Myung In Pharm Co stock

Net Profit Margin of Myung In Pharm Co is 28.35 % in 2025.

Net Profit Margin of Myung In Pharm Co changed from 25.49 % to 28.35 %, representing a 11.23% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Myung In Pharm Co since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Myung In Pharm Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Myung In Pharm Co

All Key Metrics — Myung In Pharm Co